Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | TACR2 | P21452 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27818098 | 0.97 | TDP1 (0.45) | TDP1L3MBTL1KCNH2MEN1KMT2A | |
| SCHEMBL30665021 | 0.86 | TDP1 (0.41) | TDP1L3MBTL1KCNH2MEN1KMT2A | |
| SCHEMBL293479 | 0.86 | TDP1 (0.41) | TDP1L3MBTL1KCNH2MEN1KMT2A | |
| SCHEMBL293478 | 0.84 | TDP1 (0.40) | TDP1L3MBTL1KCNH2MEN1KMT2A | |
| SCHEMBL27862457 | 0.84 | PTGS2 (0.41) | TDP1L3MBTL1KCNH2PTGS2CYP3A4 | |
| SCHEMBL10496018 | 0.84 | TDP1 (0.40) | TDP1L3MBTL1KCNH2PTGS2CYP3A4 | |
| SCHEMBL6753235 | 0.84 | TLR7 (0.46) | TDP1L3MBTL1KCNH2MEN1KMT2A | |
| SCHEMBL14776060 | 0.84 | L3MBTL1 (0.40) | TDP1L3MBTL1KCNH2MEN1KMT2A | |
| SCHEMBL22623929 | 0.83 | TDP1 (0.39) | TDP1L3MBTL1KCNH2MEN1KMT2A | |
| SCHEMBL1033248 | 0.81 | ALDH1A1 (0.40) | TDP1L3MBTL1KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0256839-B1 | SMOKING COMPOSITIONS CONTAINING A FLAVORANT ADDITIVE | Philip Morris Products Inc. (US) | 1991-11-06 | — | — | EP | claimed |
| CN-104672152-B | Organic compound and its application in the synthesis of organometallic complex | 株式会社半导体能源研究所 | 2018-09-21 | — | — | CN | disclosed |
| CN-101267838-B | Use of DPP-IV inhibitors to reduce hypoglycemic events | NOVARTIS AG | 2012-09-05 | — | — | CN | disclosed |
| WO-2011000481-A1 | SYNTHESIS OF PYRAZINE DERIVATES | MERCK PATENT GMBH (DE) | 2011-01-06 | — | — | WO | disclosed |
| CN-101267838-A | Use of DPP-IV inhibitors to reduce hypoglycemic events | NOVARTIS AG (CH) | 2008-09-17 | — | — | CN | disclosed |
| CN-101222919-A | Combination of a DPP-iv inhibitor and a cannabinoid CB1 receptor antagonist | NOVARTIS AG (CH) | 2008-07-16 | — | — | CN | disclosed |
| EP-1871762-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| CN-1867332-A | Comprising a selective CB1Combination therapy of obesity with antagonists and lipase inhibitors | SOLVAY PHARM GMBH (DE) | 2006-11-22 | — | — | CN | disclosed |
| US-6887875-B2 | Bind with high selectivity and/ or high affinity to CRF1 receptors (Corticotropin Releasing Factor 1 Receptors), useful for treating psychiatric and neurological diseases, including depression, anxiety and post trauma stress | NEUROGEN CORPORATION (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1399428-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1399428-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | NEUROGEN CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | NEUROGEN CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020161528-A1 | Tool for lipophilicity determination in drug discovery basic and neutral compounds | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| EP-1239280-A2 | ElogDoct:A tool for lipophilicity determination in drug discovery basic and neutral compounds | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-4513135-A | GAMMA-AMINOBUTYRIC ACID BINDING AGTIVATORS | ELI LILLY AND COMPANY (US) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | CRHR2, CRHR1, CRH | TDP1 966/4885L3MBTL1 4409/4885KCNH2 4424/4885 |
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | CNR2, CNR1, HTR2C | TDP1 4119/4885L3MBTL1 4181/4885KCNH2 1287/4885 |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | TDP1 4381/4885L3MBTL1 2120/4885KCNH2 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.